Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.85 |
---|---|
High | 8.85 |
Low | 8.85 |
Bid | 8.75 |
Offer | 9.15 |
Previous close | 8.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 897.56m |
Free float | 668.34m |
P/E (TTM) | -- |
Market cap | 65.75bn HKD |
EPS (TTM) | -0.9403 HKD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Press releases
- Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
- Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
More ▼